The Clinical Trials Office's (CTO) mission is to support clinical investigators in the development and implementation of clinical research studies at the Moffitt Cancer Center. The infrastructure in place assists the investigators with the following activities: ? Assisting investigators in screening and enrolling patients for clinical studies. ? Providing data management support for clinical studies. ? Assisting the Principal Investigators in the compliant conduct of clinical studies, including assisting in the submission of required regulatory documents, annual reviews and adverse event reporting. ? Providing staff training and education pertaining to clinical studies. ? Coordinating and implementing protocol related orders for study patients. ? Preparing medical and research records for audits. The CTO has seen an average combined accrual to clinical intervention, prevention intervention, and supportive care intervention trials of 2,856 subjects/year for FY's 2006-2010 (an average of 1,176 subjects/year for clinical intervention trials, 780 subjects/year for prevention intervention trials, and 872 subjects/year for supportive care intervention trials). FY 2010 was especially robust, with accruals of 1,287,2,406, and 1,001 subjects to clinical, prevention, and supportive care intervention trials, respectively. The accrual to investigator-initiated trials (external peer reviewed + institutional) for all intervention studies has remained greater than 60% for all 5 years and was 84% in FY 2010. Clearly, these accrual levels, as well as the complexity and increased data collection requirements of current trials, have necessitated growth of the CTO and demand increased efficiency. The CTO operates efficiently for the cost effective management of clinical trials at the Cancer Center. The accrual to all intervention, prevention intervention and supportive care intervention trials continues to increase on a yearly basis. The Core requests CCSG Support of $570,611, which is 13% of its operational budget.

Public Health Relevance

The centralized Clinical Trials Office provides consistent, cost-effective services by qualified research staff to support the large clinical trial portfolio generated by the Phase I program, the disease-based clinical departments (phase 11 and 111 trials), and the cancer prevention and control investigators. The core also provides standardized education and orientation to all core staff and investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-16
Application #
8613462
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$293,321
Indirect Cost
$119,243
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Akuffo, Afua A; Alontaga, Aileen Y; Metcalf, Rainer et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293:6187-6200
Mahajan, Nupam P; Coppola, Domenico; Kim, Jongphil et al. (2018) Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. Sci Rep 8:1954
Gonzalez, Brian D; Hoogland, Aasha I; Kasting, Monica L et al. (2018) Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 27:2778-2785
Christy, Shannon M; Schmidt, Alyssa; Wang, Hsiao-Lan et al. (2018) Understanding Cancer Worry Among Patients in a Community Clinic-Based Colorectal Cancer Screening Intervention Study. Nurs Res 67:275-285
Chang, James M; Kosiorek, Heidi E; Dueck, Amylou C et al. (2018) Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg 215:699-706
Rounbehler, Robert J; Berglund, Anders E; Gerke, Travis et al. (2018) Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:1376-1383
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Porubsky, Caitlin; Teer, Jamie K; Zhang, Yonghong et al. (2018) Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol 45:180-183
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Li, Yafang; Xiao, Xiangjun; Han, Younghun et al. (2018) Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis 39:336-346

Showing the most recent 10 out of 1254 publications